MONT-SAINT-HILAIRE, QUEBEC--(MARKET WIRE)--Aug 2, 2007 -- Axcan Pharma Inc. (“Axcan” or the “Company”) (Toronto:AXP.TO - News)(NasdaqGS:AXCA - News) today announced that it has submitted the complete New Drug Application (“NDA”) for ULTRASE in the treatment of Exocrine Pancreatic Insufficiency (“EPI”), with the U.S. Food and Drug Administration (“FDA”). The FDA had already granted ULTRASE a Fast Track designation, which allows promising new drugs and biological products that treat serious, life-threatening or severely debilitating diseases to proceed more rapidly through the regulatory process.
